• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    GridAI Technologies Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    5/14/26 4:01:34 PM ET
    $GRDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GRDX alert in real time by email
    false 0001604191 0001604191 2026-05-08 2026-05-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of report (Date of earliest event reported): May 8, 2026

     

    GridAI Technologies Corp.
    (Exact name of registrant as specified in its charter)

     

    Delaware   001-37853   46-4993860
    (State or other jurisdiction of
    incorporation)
      (Commission File Number)   (IRS Employer Identification No.)

     

    433 Plaza Real, Suite 275

    Boca Raton, Florida

      33432
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (561) 589-7020

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)  

    Name of each exchange on which
    registered

    Common Stock, par value $0.0001 per share   GRDX   Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 1.01. Entry Into a Material Definitive Agreement

     

    $2.54 million Financing

     

    On May 8, 2026, May 11, 2026 and May 12, 2026, GridAI Technologies Corp. (the “Company”) entered into securities purchase agreements (the “Purchase Agreements”) with purchasers identified therein (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”) pursuant to which the Company agreed to sell to the Purchasers in private placements an aggregate of (i) 74,000 shares of common stock, (ii) pre-funded warrants to purchase up to an aggregate of 1,196,001 shares of common stock (the “Pre-Funded Warrants”) and (iii) common stock purchase warrants to purchase up to an aggregate of 1,270,001 shares of common stock (the “Common Warrants”) for gross proceeds to the Company of approximately $2,540,000. The combined purchase price for one share of common stock or Pre-Funded Warrant in lieu of share of common stock and one Common Warrants is $2.00.

     

    The Company intends to use the net proceeds for general corporate purposes, including working capital, and repayment of certain outstanding liabilities. The closing will occur on May 18, 2026, subject to the satisfaction of customary closing conditions.

     

    All Pre-Funded Warrants have an exercise price of $0.00001 per share, subject to adjustment and no expiration date. The Pre-Funded Warrants will be exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full.

     

    The Common Warrants are exercisable six months after the issuance date and expire five years from the earlier of the effective date of the Registration Statement or the date that the common stock underlying the Pre-Funded Warrants and Common Warrants can be resold without restriction or limitation pursuant to Rule 144. The Common Warrants issuable pursuant to the Purchase Agreement dated May 8, 2026 have an exercise price of $2.56 per share, the Common Warrants issuable pursuant to the Purchase Agreement dated May 11, 2026 have an exercise price of $2.74 per share and the Common Warrants issuable pursuant to the Purchase Agreement dated May 12, 2026 have an exercise price of $2.89 per share, all subject to adjustment as set forth in the Common Warrants for stock splits, stock dividends, recapitalizations and similar customary adjustments. The Purchasers may exercise the Common Warrants on a cashless basis if the shares of common stock underlying the Common Warrants are not then registered pursuant to an effective registration statement. Certain Purchasers have contractually agreed to restrict its ability to exercise the Common Warrant such that the number of shares of the Company’s common stock held by the Purchaser and its affiliates after such exercise does not exceed the Beneficial Ownership Limitation set forth in the Common Warrant which may not exceed 4.99% (or, upon election by a Purchaser prior to the issuance of any Common Warrants, 9.99%) of the Company’s then issued and outstanding shares of common stock.

     

     

     

     

    In connection with the Purchase Agreement, the Company entered into registration rights agreements (the “Registration Rights Agreements”) with the Purchasers. Pursuant to the Registration Rights Agreements, the Company will be required to file a resale registration statement (the "Registration Statement") with the Securities and Exchange Commission to register for resale the shares issuable upon exercise of the Pre-Funded Warrants and the shares issuable upon exercise of the Common Warrants within 15 days after the closing of the transactions contemplated by the Purchase Agreements, and to have such Registration Statement declared effective as promptly as possible after its filing.

     

    The foregoing descriptions of the Purchase Agreements, Pre-Funded Warrants, Common Warrants, and Registration Rights Agreements described herein are subject to, and qualified in their entirety by, such documents, which are filed as Exhibit 10.1, 4.1, 4.2, and 10.2 to this Current Report on Form 8-K and incorporated herein by reference.

     

    $5.25 million Financining

     

    On May 11, 2026, the Company entered into a securities purchase agreement (the “Additional Purchase Agreement”) with the purchasers identified therein (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”) pursuant to which the Company will sell to the Purchasers in private placements an aggregate of (i) 87,260 shares of common stock, (ii) pre-funded warrants to purchase up to an aggregate of 1,745,199 shares of common stock (the “Pre-Funded Warrants”) and (iii) common stock purchase warrants to purchase up to an aggregate of 1,832,459 shares of common stock (the “Common Warrants”) for gross proceeds to the Company of approximately $5,250,000. The combined purchase price for one share of common stock or Pre-Funded Warrant in lieu of share of common stock and one Common Warrants is $2.865.

     

    The Company intends to use the net proceeds for general corporate purposes, including working capital, and repayment of certain outstanding liabilities. The closing will occur on May 18, 2026, subject to the satisfaction of customary closing conditions. $20% of the gross proceeds will be paid to the Company at closing. The remaining 80% of the proceeds will be paid prior to the declaration by the Securities and Exhange Commission (the “SEC”) that the Registration Statement (defined below) is effective.

     

    The Pre-Funded Warrants have an exercise price of $0.00001 per share, subject to adjustment and no expiration date. The Pre-Funded Warrants will be exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full.

     

    The Common Warrants are exercisable immediately and expire five years from the earlier of the effective date of the Registration Statement or the date that the common stock underlying the Pre-Funded Warrants and Common Warrants can be resold without restriction or limitation pursuant to Rule 144. The Common Warrants have an exercise price of $2.865 per share, subject to adjustment as set forth in the Common Warrants for stock splits, stock dividends, recapitalizations and similar customary adjustments. The Purchasers may exercise the Common Warrants on a cashless basis if the shares of common stock underlying the Common Warrants are not then registered pursuant to an effective registration statement.

     

    In connection with the Additional Purchase Agreement, the Company entered into registration rights agreements (the “Registration Rights Agreements”) with the Purchasers. Pursuant to the Registration Rights Agreements, the Company will be required to file a resale registration statement (the "Registration Statement") with the SEC to register for resale the shares issued under the Additional Purchase Agreement, the shares issuable upon exercise of the Pre-Funded Warrants and the shares issuable upon exercise of the Common Warrants, within 15 days after the closing of the transactions contemplated by the Additional Purchase Agreement, and to have such Registration Statement declared effective as promptly as possible after its filing.

     

    The foregoing descriptions of the Additional Purchase Agreement, Pre-Funded Warrants, Warrants, and Registration Rights Agreements described herein are subject to, and qualified in their entirety by, such documents, which are filed as Exhibit 10.3, 4.1, 4.3 and 10.2 to this Current Report on Form 8-K and incorporated herein by reference.

     

    Item 3.02 Unregistered Sales of Equity Securities.

     

    The disclosure under Item 1.01 above is incorporated herein by reference. In connection with the issuance of the securities described in Item 1.01, the Company relied upon the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended, for transactions not involving a public offering.

     

     

     

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit
    No.
      Description
    4.1   Form of Pre-Funded Warrant
    4.2   Form of Warrant
    4.3   Form of Warrant
    10.1   Form of Securities Purchase Agreement
    10.2   Form of Registration Rights Agreement
    10.3   Form of Securities Purchase Agreement
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      GridAI Technologies Corp.
       
    May 14, 2026 By: /s/ Jason D. Sawyer
      Name: Jason D. Sawyer
      Title: Chief Executive Officer

     

     

     

    Get the next $GRDX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GRDX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GRDX
    SEC Filings

    View All

    SEC Form 10-Q filed by GridAI Technologies Corp.

    10-Q - GridAI Technologies Corp. (0001604191) (Filer)

    5/27/26 6:04:42 AM ET
    $GRDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GridAI Technologies Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - GridAI Technologies Corp. (0001604191) (Filer)

    5/20/26 4:06:01 PM ET
    $GRDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form NT 10-Q filed by GridAI Technologies Corp.

    NT 10-Q - GridAI Technologies Corp. (0001604191) (Filer)

    5/15/26 4:01:25 PM ET
    $GRDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GRDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Syage Jack was granted 40,000 shares (SEC Form 4)

    4 - GridAI Technologies Corp. (0001604191) (Issuer)

    6/3/26 8:11:28 PM ET
    $GRDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Borkowski Edward was granted 40,000 shares, increasing direct ownership by 198% to 60,248 units (SEC Form 4)

    4 - GridAI Technologies Corp. (0001604191) (Issuer)

    1/8/26 5:28:29 PM ET
    $GRDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Uppal Manpreet was granted 40,000 shares (SEC Form 4)

    4 - GridAI Technologies Corp. (0001604191) (Issuer)

    1/5/26 5:24:51 PM ET
    $GRDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GRDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Powell Max Limited Successfully Repositions for Its Next Phase of Growth

    Hong Kong, TX, March 09, 2026 (GLOBE NEWSWIRE) -- Powell Max Limited (NASDAQ:PMAX) ("Powell Max" or the "Company"), a financial communications services provider, is pleased to provide the following corporate update regarding its successful repositioning. Key Highlights: Raised $17 million in capital from new investorsAppointed new Chairman and Chief Executive Officer Geordan PursgloveReconstituted the Board of DirectorsRegained compliance with Nasdaq listing requirements Powell Max Chairman and Chief Executive Officer Geordan Pursglove commented, "My first month at Powell Max has been extremely productive. We successfully completed a corporate restructuring in a short timeframe, raised

    3/9/26 8:30:00 AM ET
    $ALBT
    $CISO
    $GRDX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Professional Services
    Consumer Discretionary

    IBN Announces Latest Episode of The TechMediaWire Podcast featuring Marshall Chapin, CEO of Grid AI Corp.

    AUSTIN, Texas, March 05, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The TechMediaWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The TechMediaWire Podcast delivers informative updates and exclusive interviews with executives operating in the tech industry. The TechMediaWire Podcast's latest episode features Marshall Chapin, CEO of Grid AI Corp., wholly-owned by GridAI Technologies Corp. (NASDAQ:GRDX), a technology company focused on intelligent en

    3/5/26 8:00:00 AM ET
    $GRDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GridAI Technologies Corp. Appoints Veteran Energy Executive Tim Healy as Executive Chairman of Grid AI Corp.

    BOCA RATON, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- via IBN – GridAI Technologies Corp. (NASDAQ:GRDX), a technology company focused on intelligent energy orchestration for hyperscale AI data centers, today announced the appointment of Tim Healy as Executive Chairman of the Board of Grid AI Corp., the Company's wholly owned operating subsidiary. Healy brings more than two decades of experience as a founder, CEO, board leader, and investor across the energy technology and energy transition landscape. Over his career, he has founded multiple public companies, establishing a track record of scaling innovative platforms from early commercialization through global deployment and strategic exits

    2/4/26 8:00:00 AM ET
    $GRDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GRDX
    Leadership Updates

    Live Leadership Updates

    View All

    GridAI Technologies Corp. Appoints Veteran Energy Executive Tim Healy as Executive Chairman of Grid AI Corp.

    BOCA RATON, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- via IBN – GridAI Technologies Corp. (NASDAQ:GRDX), a technology company focused on intelligent energy orchestration for hyperscale AI data centers, today announced the appointment of Tim Healy as Executive Chairman of the Board of Grid AI Corp., the Company's wholly owned operating subsidiary. Healy brings more than two decades of experience as a founder, CEO, board leader, and investor across the energy technology and energy transition landscape. Over his career, he has founded multiple public companies, establishing a track record of scaling innovative platforms from early commercialization through global deployment and strategic exits

    2/4/26 8:00:00 AM ET
    $GRDX
    Biotechnology: Pharmaceutical Preparations
    Health Care